Sight Sciences

SGHT · NASDAQ

$8.62+$0.36 (+4.36%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $8.26

SGHT analyst rating

BuyConsensus of 8 analysts over the last 12 months. 75% rate it a buy.

Strong buy0
Buy6
Hold2
Underperform0
Sell0

12-month price target · 8 analysts

Average $9.01 (+4.5% upside)

Low: $8.08
Now: $8.62
High: $12.60

Upgrades and downgrades

The latest rating actions, newest first

SGHT analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
HC Wainwright & Co.	Oct 15, 2026	Initiates	Buy	$14.00	40%
Citigroup	Oct 5, 2026	Maintains	Neutral	$8.00 → $10.00	60%
Citigroup	Aug 17, 2026	Maintains	Neutral	$6.00 → $8.00	60%
UBS	Aug 6, 2026	Maintains	Buy	$7.00 → $8.00	43%
UBS	Jul 28, 2026	Initiates	Buy	$11.00 → $7.00	43%
Citigroup	Jul 8, 2026	Maintains	Neutral	$5.15 → $6.00	60%
Citigroup	May 28, 2026	Maintains	Neutral	$4.35 → $5.15	60%
UBS	Mar 6, 2026	Maintains	Buy	$12.00 → $11.00	50%
Citigroup	Mar 6, 2026	Maintains	Neutral	$9.10 → $6.50	60%
Stifel	Mar 2, 2026	Maintains	Buy	$6.00 → $8.00	33%

The case for and against

Updated Feb 9, 2026

Bull case

Sight Sciences Inc. exhibits a positive financial outlook driven by anticipated stronger revenue growth, stemming from an expected increase in market share within the minimally invasive glaucoma surgery (MIGS) sector and more rapid adoption of its TearCare System. The company's Surgical Glaucoma segment is projected to sustain growth consistent with the overall MIGS market, positioning Sight Sciences for enhanced financial performance. Furthermore, analysts have maintained revenue projections of $75 million for 2025 and $82 million for 2026, while also showing improvement in earnings per share (EPS) estimates, indicating ongoing progress towards profitability.

Bear case

Sight Sciences Inc. faces a challenging financial outlook as it reiterated its 2025 revenue guidance of $72-76 million while anticipating mid-single-digit year-over-year declines in its Surgical Glaucoma segment for Q3 2025. The company confronts significant risks, including increasing competition in the minimally invasive glaucoma surgery (MIGS) market, delayed insurance coverage for its TearCare system, and persistent cash burn with no signs of improvement. Additionally, management has lowered its adjusted operating expense guidance for 2025, indicating struggles in managing costs despite efforts to achieve annualized savings through a reduction in workforce.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.